Canadian biotech Ceapro announced the expansion of an existing collaboration with McMaster University for development of inhaled yeast beta glucans for the prevention and treatment of lung fibrosis caused by COVID-19. According to Ceapro, the team has already successfully created inhalable yeast beta glucan particles via PGX and now plans to optimize delivery and … [Read more...] about Ceapro expands collaboration with McMaster University on development of inhaled yeast beta glucans
News
Harm Reduction signs supply agreement for RiVive naloxone nasal spray after getting Fast Track designation
Harm Reduction Therapeutics announced that it has signed a commercial supply agreement for its RiVive (HRT001) intranasal naloxone after the FDA granted Fast Track designation to the nasal spray, which is in development as a low cost OTC product for the reversal of opioid overdose. HRT did not name the company it contracted with but said that RiVive would be … [Read more...] about Harm Reduction signs supply agreement for RiVive naloxone nasal spray after getting Fast Track designation
Aridis says that its AR-701 inhaled mAb cocktail is effective against SARS-CoV-2 in macaques
Aridis Pharmaceuticals said that its AR-701 inhaled monoclonal antibody cocktail effectively reduced viral load in rhesus macaques infected with SARS-CoV-2 and protected against lung disease in those animals over a 5-day period. The company received $1.9 million from the Bill & Melinda Gates Foundation in January 2022 for preclinical development of its inhaled … [Read more...] about Aridis says that its AR-701 inhaled mAb cocktail is effective against SARS-CoV-2 in macaques
Opiant gets addition $2.1 million from BARDA for OPNT003
Opiant Pharmaceuticals said that it has received an additional $2.1 million from the US Biomedical Advanced Research and Development Authority (BARDA) to support regulatory activities related to its OPNT003 intranasal nalmefene for the treatment of opioid overdose. BARDA had already provided an additional $2.2 million for OPNT003 earlier this year, and the total … [Read more...] about Opiant gets addition $2.1 million from BARDA for OPNT003
Verona announces that Phase 3 trial of nebulized ensifentrine for COPD met its primary endpoint
Verona Pharma said that the Phase 3 ENHANCE-2 trial of nebulized ensifentrine for treatment of COPD met its primary endpoint, with an average change from baseline in FEV1 AUC, 0-12 hours post dose, of 94 ml at week 12. In addition, a number of secondary endpoints were met, and for patients who got ensifentrine, the rate of exacerbations was reduced by 42% over 24 … [Read more...] about Verona announces that Phase 3 trial of nebulized ensifentrine for COPD met its primary endpoint
Innovate UK awards £1 million grant to Acu-Flow for development of Nebu-Flow technology
The University of Glasgow announced that Innovate UK has awarded a university spinout, Acu-Flow, £1 million for development of the company's Nebu-Flow surface acoustic wave nebulizer technology. The University said that its researchers will work with Acu-Flow and the NIHR Devices for Dignity Med-tech Cooperative to have a working nebulizer ready for manufacturing … [Read more...] about Innovate UK awards £1 million grant to Acu-Flow for development of Nebu-Flow technology
Aptar Pharma acquires rights to Pharmaxis’ Orbital DPI
Aptar Pharma announced that it has acquired worldwide rights to Pharmaxis’ high payload Orbital dry powder inhaler. In August 2021, the company said that it had acquired an option to purchase the rights to the Orbital DPI and that it had 12 months to decide whether or not to exercise that option. The Orbital inhaler can handle total doses up to 400 mg and was … [Read more...] about Aptar Pharma acquires rights to Pharmaxis’ Orbital DPI
FDA to provide funding for study to validate Inhalation Sciences’ DissolvIt lung simulation model for dissolution testing of inhaled drugs
According to Inhalation Sciences (ISAB), the FDA will provide up to $500,000 over two years to fund a study intended to validate ISAB's DissolvIt in vitro lung simulation model for dissolution testing of inhaled drugs. The company said that the agency's National Center for Toxicological Research has approved the research proposal, and the study is expected to begin … [Read more...] about FDA to provide funding for study to validate Inhalation Sciences’ DissolvIt lung simulation model for dissolution testing of inhaled drugs
Adherium submits 510(k) application for a Hailie sensor for use with Ventolin, Advair, and Flovent MDIs
Just over a week after receiving 510(k) clearance for a Hailie inhaler sensor for use with Ellipta DPIs, Adherium said that it filed a 510(k) submission to the FDA for a new Hailie sensor to be used with GSK's Ventolin, Advair, and Flovent MDIs. The new Hailie sensor measures various parameters, including respiratory flow rate, and connects to the company's Hailie … [Read more...] about Adherium submits 510(k) application for a Hailie sensor for use with Ventolin, Advair, and Flovent MDIs
Renovion announces planned Phase 3 trial of ARINA-1 inhaled mucolytic in bilateral lung transplant patients
Renovion announced that the company has gotten the go-ahead from the FDA to initiate a Phase 3 clinical trial of its ARINA-1 nebulized glutathione / bicarbonate / ascorbic acid for the prevention of bronchiolitis obliterans in bilateral lung transplant patients who have recently had a reduction in lung function. ARINA-1, which is delivered via the PARI eFlow nebulizer … [Read more...] about Renovion announces planned Phase 3 trial of ARINA-1 inhaled mucolytic in bilateral lung transplant patients